거대세포바이러스 치료 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, cytomegalovirus treatment market size in 2026 is estimated at USD 367.36 million, growing from 2025 value of USD 345.91 million with 2031 projections showing USD 496.27 million, growing at 6.20% CAGR over 2026-2031.

This report is Segmented by Drug Class (DNA-Polymerase Inhibitors, Terminase Inhibitors, Other Drug Class), Application (Hematopoietic Stem-Cell Transplantation, and More), Route of Administration (Oral, and More), Distribution Channel (Hospital Pharmacies, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Cytomegalovirus Treatment Market Trends and Insights

Expansion of HSCT & SOT Procedures Fuelling Prophylactic Prescriptions

Rising hematopoietic stem-cell and solid-organ transplant volumes are enlarging the at-risk population, prompting routine prophylaxis with agents such as letermovir. The increasing number of Hematopoietic Stem Cell Transplantation procedures worldwide continues to strengthen demand for effective cytomegalovirus prevention and treatment therapies. Adoption of post-transplant cyclophosphamide and haploidentical protocols widens donor pools yet heightens CMV reactivation risk, reinforcing demand for low-toxicity prophylactics. Merck's Phase 3 data in kidney transplantation broadened letermovir's clinical utility and showcased superior safety profiles that reduce hospital stays by an average 12 days, creating a compelling pharmacoeconomic case for widespread use.

Expanding Newborn Screening Programs for Congenital CMV

Universal newborn screening has moved from pilot to policy in several US states. Minnesota identified 184 cases during its first year, revealing a 0.3% prevalence and validating pooled-saliva testing efficiencies that cut individual assays by 83%. Early detection permits timely valganciclovir therapy for symptomatic infants and catalyzes a nascent pediatric segment within the cytomegalovirus treatment market.

Toxicity & Adverse-Event Profile of Existing Antivirals

Valganciclovir-induced leukopenia and neutropenia continue to prompt dose reductions and hospitalizations, affecting 24.4% and 69.7% of kidney transplant patients, respectively. The resultant resource burden strengthens the competitive positioning of better-tolerated terminase inhibitors, but it also imposes near-term friction on adoption curves for the cytomegalovirus treatment market.

Other drivers and restraints analyzed in the detailed report include:

1. FDA & EMA Approvals of Novel Antivirals
2. Shift to Home/Ambulatory Infusion Lowering Treatment Barriers
3. Rising Antiviral-Resistant CMV Strains

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

DNA-polymerase inhibitors accounted for 57.66% of 2025 revenue, underscoring decades of clinical familiarity. Yet, terminase inhibitors are growing at 11.32% CAGR as clinicians pivot to letermovir for prophylaxis, citing negligible myelotoxicity. The cytomegalovirus treatment market size for terminase inhibitors is forecast to swell meaningfully as new indications win approval. Meanwhile, UL97 kinase inhibitors and cell-based therapies, though smaller, provide strategic options for refractory or resistant cases and attract investment from firms with advanced biomanufacturing capacity.

Emerging cell-therapy entrants are forging alliances with contract manufacturers to overcome production bottlenecks. Despite intricate logistics, successful commercialization could redefine the cytomegalovirus treatment market by offering curative, patient-specific solutions, a disruptive prospect that incentivizes incumbent antiviral producers to diversify pipelines.

Hematopoietic stem-cell transplantation maintained a 45.35% share in 2025, yet solid-organ transplantation is advancing at a 12.65% CAGR as kidney, liver, and lung transplants rise globally. This growth underpins demand for safer long-term prophylaxis regimens and pushes developers to tailor dosing to organ-specific immunosuppression protocols, reinforcing the cytomegalovirus treatment market's shift toward personalized management.

Congenital CMV, catalyzed by universal screening, opens a pediatric niche. Symptomatic infants derive measurable neurodevelopmental benefit from early valganciclovir, while asymptomatic cases are now flagged earlier, expanding the cytomegalovirus treatment market's future addressable base. Concurrently, HIV and other immunocompromised conditions represent a steady-state submarket where letermovir shows potential to reduce systemic inflammation and improve immune metrics.

Complete Report Scope:

• By Drug Class
  • DNA-Polymerase Inhibitors
  • Terminase Inhibitors
  • Other Drug Class
• By Application
  • Hematopoietic Stem-Cell Transplantation
  • Solid-Organ Transplantation
  • Congenital CMV Infection
  • HIV/AIDS & Other Immunocompromised Conditions
• By Route of Administration
  • Oral
  • Intravenous
  • Topical / Intra-ocular
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-commerce & Specialty Infusion Providers
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 41.12% of global revenue in 2025, leveraging advanced transplant infrastructure, generous reimbursement, and leadership in universal newborn screening. FDA approvals such as Prevymis for kidney transplantation underscore the region's innovation edge and expand preventive care to broader patient cohorts.

Europe follows with mature transplant networks and EMA-aligned protocols that integrate cost-effectiveness considerations. Rapid pan-EU uptake of letermovir reflects clinician confidence in its safety and economic value, while real-world evidence programs generate data that inform global practice guidelines. Regulatory harmonization continues despite post-Brexit adjustments, sustaining Europe's position as a key cytomegalovirus treatment market for multinational players.

Asia-Pacific is the fastest-growing region at 11.98% CAGR through 2031. Japan's 2024 Livtencity approval opened the gate for cutting-edge therapies, and expanding programs in China and India signal rising demand. Local manufacturing partnerships provide cost-competitive supply, while national reimbursement schemes gradually adjust to include high-value antivirals. Middle East & Africa and South America, though smaller, exhibit improving transplant capabilities and rising CMV awareness, presenting long-term expansion prospects.

1. Merck
2. Roche
3. Gilead Sciences
4. Pfizer
5. Takeda Pharmaceutical Co.
6. Chimerix Inc.
7. Clinigen Group
8. Fresenius
9. Teva Pharmaceutical Industries
10. Thermo Fisher Scientific
11. Astellas Pharma
12. CSL Behring
13. AiCuris Anti-infective Cures AG
14. Atara Biotherapeutics Inc.
15. Moderna
16. Abbvie
17. Mylan N.V. (Viatris)
18. Genentech
19. Vical Inc.
20. Shionogi

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Expansion of HSCT & SOT Procedures Fuelling Prophylactic Prescriptions
  • 4.2.2 Expanding Newborn-Screening Programs for Congenital CMV
  • 4.2.3 FDA & EMA Approvals of Novel Antivirals
  • 4.2.4 Shift to Home/Ambulatory Infusion Lowering Treatment Barriers
  • 4.2.5 Adoption of CMV-Specific T-Cell Therapies for Refractory Disease
  • 4.2.6 Hospital Budget Savings Data Accelerating Letermovir Uptake
• 4.3 Market Restraints
  • 4.3.1 Toxicity & Adverse-Event Profile of Existing Antivirals
  • 4.3.2 Rising Antiviral-Resistant CMV Strains
  • 4.3.3 Reimbursement Hurdles for Novel Prophylaxis
  • 4.3.4 Manufacturing Complexity for Cell-Based CMV Therapies
• 4.4 Porter's Five Forces Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitutes
  • 4.4.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value in USD)

• 5.1 By Drug Class
  • 5.1.1 DNA-Polymerase Inhibitors
  • 5.1.2 Terminase Inhibitors
  • 5.1.3 Other Drug Class
• 5.2 By Application
  • 5.2.1 Hematopoietic Stem-Cell Transplantation
  • 5.2.2 Solid-Organ Transplantation
  • 5.2.3 Congenital CMV Infection
  • 5.2.4 HIV/AIDS & Other Immunocompromised Conditions
• 5.3 By Route of Administration
  • 5.3.1 Oral
  • 5.3.2 Intravenous
  • 5.3.3 Topical / Intra-ocular
• 5.4 By Distribution Channel
  • 5.4.1 Hospital Pharmacies
  • 5.4.2 Retail Pharmacies
  • 5.4.3 E-commerce & Specialty Infusion Providers
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Merck & Co. Inc.
  • 6.3.2 F. Hoffmann-La Roche Ltd
  • 6.3.3 Gilead Sciences Inc.
  • 6.3.4 Pfizer Inc.
  • 6.3.5 Takeda Pharmaceutical Co.
  • 6.3.6 Chimerix Inc.
  • 6.3.7 Clinigen Group PLC
  • 6.3.8 Fresenius Kabi
  • 6.3.9 Teva Pharmaceutical Industries Ltd
  • 6.3.10 Thermo Fisher Scientific Inc.
  • 6.3.11 Astellas Pharma Inc.
  • 6.3.12 CSL Behring
  • 6.3.13 AiCuris Anti-infective Cures AG
  • 6.3.14 Atara Biotherapeutics Inc.
  • 6.3.15 Moderna Inc.
  • 6.3.16 AbbVie Inc.
  • 6.3.17 Mylan N.V. (Viatris)
  • 6.3.18 Genentech Inc.
  • 6.3.19 Vical Inc.
  • 6.3.20 Shionogi & Co. Ltd

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment